Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Endpoints Could Help Chronic Condition Drugs Switch

This article was originally published in The Tan Sheet

Executive Summary

Companies attempting to switch a drug OTC for a chronic condition might have a stronger case if supported by data focusing on clinical endpoints rather than just markers, a workshop group surmised at the Consumer Healthcare Products Association Research & Scientific Development Conference in Washington, D.C. Oct. 28-29.

You may also be interested in...

Questran second advisory committee divided on OTC switch recommendation.

QUESTRAN ADVISORY COMMITTEE EVENLY SPLIT ON OTC SUITABILITY after a reconsideration of Bristol-Myers Squibb's application to switch its Questran (cholestyramine) and Questran Light from prescription to OTC status for the treatment of hypercholesterolemia. At a May 13 meeting in Bethesda, Md., members of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committee voted five to five with one abstention on the suitability of the switch.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts